erlotinib hydrochloride has been researched along with picropodophyllin in 2 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (picropodophyllin) | Trials (picropodophyllin) | Recent Studies (post-2010) (picropodophyllin) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 134 | 3 | 80 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH | 1 |
Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
1 review(s) available for erlotinib hydrochloride and picropodophyllin
Article | Year |
---|---|
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
1 other study(ies) available for erlotinib hydrochloride and picropodophyllin
Article | Year |
---|---|
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |